Becton, Dickinson and Company $BDX Shares Sold by Truist Financial Corp

Truist Financial Corp trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 46.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 93,400 shares of the medical instruments supplier’s stock after selling 82,564 shares during the period. Truist Financial Corp’s holdings in Becton, Dickinson and Company were worth $17,482,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of BDX. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. RiverGlades Family Offices LLC purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at $344,000. Strs Ohio boosted its position in shares of Becton, Dickinson and Company by 31.7% in the third quarter. Strs Ohio now owns 301,430 shares of the medical instruments supplier’s stock worth $56,419,000 after buying an additional 72,626 shares during the period. Covea Finance grew its holdings in shares of Becton, Dickinson and Company by 10.7% during the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock valued at $14,758,000 after buying an additional 7,610 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Becton, Dickinson and Company during the second quarter valued at $983,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,680 shares of company stock worth $539,848 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BDX. Royal Bank Of Canada raised their price objective on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 17th. Bank of America increased their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Jefferies Financial Group boosted their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $209.00.

Becton, Dickinson and Company Trading Up 1.2%

Shares of NYSE:BDX opened at $203.56 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $58.00 billion, a PE ratio of 34.92, a P/E/G ratio of 2.22 and a beta of 0.23. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The firm has a fifty day moving average price of $198.54 and a 200 day moving average price of $191.24.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion during the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.